Copyright 2003 Business Wire, Inc.
Business Wire
July 29, 2003, Tuesday
DISTRIBUTION: Business Editors
LENGTH: 731 words
HEADLINE: The Quigley Corporation Receives US Patents for its New Formulation Being Tested to Relieve Sialorrhea
DATELINE: DOYLESTOWN, Pa., July 29, 2003

The Second & Third in a Series of Potential Drug Patents Granted to The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY), www.quigleyco.com, a leading developer and marketer of diversified health products, today announced that it has received two patents for its compound QR-334, a new formulation currently being tested in clinical trials to relieve Sialorrhea, excess secretions of the salivary glands. The U.S. Patent, No. 6,592,896 is entitled "Medicinal Composition and Method of Using It" and extends through August 6, 2021 and the U.S. Patent, No. 6,596,313 is entitled "Nutritional Supplement and Method of Using It" and extends through April 15, 2022.

Sialorrhea is a condition that affects patients suffering from diseases including Amyotrophic Lateral Sclerosis (ALS), otherwise known as Lou Gehrig's Disease, Cerebral Palsy, Parkinson's Disease, and Muscular Dystrophy among others. Although there is no published data summarizing all the patients suffering from this condition, Sialorrhea may affect several million patients annually suffering from these diverse diseases.

"The issuance of these patents for QR-334 is a significant milestone and will help protect the tremendous research, hard work, and investment that went into developing this product," said Guy Quigley, President and CEO of The Quigley Corporation. "Currently there is no completely safe therapy documented to resolve Sialorrhea satisfactorily in all patients without significant side effects."

The Principal Investigator for QR-334's clinical trial is Dr. Stanley H. Appel, Professor and Chairman of the Department of Neurology at the Baylor College of Medicine, Texas Medical Center, in Houston. This trial is a multi center U.S. study that includes approximately 100 patients at clinical sites at Baylor College of Medicine, Houston, Texas, the University of Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School (UMDNJ-RWJ) and other private clinical research centers in Philadelphia, Louisville, Tampa and LaJolla, California.

QR-334 is the second in a series of potential drug targets for The Quigley Corporation through its wholly-owned subsidiary, Quigley Pharma. In addition to QR-334, Quigley has received a patent for QR-333, a topical compound being tested for the pain associated with diabetic peripheral neuropathy. A recent Phase II proof of concept study for its QR-333 formula concluded that subjects taking QR-333 had 67% of their symptoms improve, strongly suggesting efficacy. The Company is also developing compounds to potentially treat radiation dermatitis, influenza A and B, herpes and psoriasis/eczema.

No claims are made that the compounds discussed herein are safe, effective, or approved by the federal Food and Drug Administration (FDA).